Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + talcum powder
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Intrapleural
01
Overview
afatinib + talcum powder is a combination treatment approach being evaluated for patients with EGFR-positive non-small cell lung cancer (NSCLC) and malignant pleural effusion. Developed by Center Trials & Treatment Europe, the therapy involves the intrapleural administration of a suspension containing talcum powder and afatinib. Talcum powder acts as a sclerosing agent, inducing chemical inflammation and pleurodesis to cause adhesion between the visceral and parietal pleura, thereby preventing the recurrence of fluid accumulation. Afatinib is a second-generation, irreversible tyrosine kinase inhibitor that targets the ErbB family of receptors, including EGFR (ErbB1), HER2 (ErbB2), and ErbB4. The combination aims to provide both mechanical control of the effusion and localized anti-tumor activity against metastatic cells in the pleural cavity.
- Other names
- talc-afatinib suspensionafatinib and talc pleurodesis
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on afatinib + talcum powder.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + talcum powder.